Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Mesothelioma 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

Pemetrexed 8pembrolizumab 6Cisplatin 6LMB-100 3Carboplatin 3Radiosurgery 2Plicamycin 2Dexamethasone 2Cryotherapy 2vandetanib 1tremelimumab 1tocilizumab 1rebastinib 1pevonedistat 1perflutren 1nintedanib 1iodixanol 1fludarabine phosphate 1fludarabine 1epacadostat 1enzalutamide 1durvalumab 1defactinib 1anetumab ravtansine 1amatuximab 1alvocidib 1aldesleukin 1Vinorelbine 1Sulfur Hexafluoride 1Radiotherapy, Intensity-Modulated 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Mesothelioma × anetumab ravtansine × Clear all
NCT03926143 2023-08-04

A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies

Bayer

Phase 2 Terminated
9 enrolled 10 charts
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡